Abstract
Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.
Keywords: Hypertension, antihypertensive treatment, beta-blocker, cardiovascular risk, beta-blockers, blood pressure, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, timolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, National Institute for Health and Clinical Excellence, ESH/ESC 2007, European Lacidipine Study on Atherosclerosis, Losar-tan Intervention For Endpoint, Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Low-ering Arm, International Verapamil-Trandolapril Study, Metoprolol Atherosclerosis Prevention in Hypertension, ACE inhibitors, Conduit Artery Function Evaluation, Canadian Hypertension Education Program, coronary artery disease CHF, congestive heart failure
Current Vascular Pharmacology
Title: Current Place of Beta-Blockers in the Treatment of Hypertension
Volume: 8 Issue: 6
Author(s): Agata Bielecka-Dabrowa, Wilbert S. Aronow, Jacek Rysz and Maciej Banach
Affiliation:
Keywords: Hypertension, antihypertensive treatment, beta-blocker, cardiovascular risk, beta-blockers, blood pressure, carteolol, carvedilol, labetalol, nadolol, penbutolol, pindolol, propranolol, timolol, atenolol, betaxolol, bisoprolol, metoprolol, nebivolol, diuretics, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, calcium channel blockers, National Institute for Health and Clinical Excellence, ESH/ESC 2007, European Lacidipine Study on Atherosclerosis, Losar-tan Intervention For Endpoint, Anglo-Scandinavian Cardiac Outcomes Trial, Blood Pressure Low-ering Arm, International Verapamil-Trandolapril Study, Metoprolol Atherosclerosis Prevention in Hypertension, ACE inhibitors, Conduit Artery Function Evaluation, Canadian Hypertension Education Program, coronary artery disease CHF, congestive heart failure
Abstract: Hypertension represents the most common cardiovascular risk factor, affecting more than 25% of the adult population in developed societies. Although beta-blockers have been previously shown to effectively reduce blood pressure and have been used for hypertension treatment for over 40 years, their effect on cardiovascular morbidity and mortality in hypertensive patients remains controversial and their use in uncomplicated hypertension is currently still under debate. According to the previous recommendations beta-blockers should not be preferred as first-line therapy in hypertension patients. This review summarizes the current knowledge on application of beta-blockers in patients with hypertension and discusses the most recent guidelines of the European Society of Hypertension (2009) on beta-blockers applications.
Export Options
About this article
Cite this article as:
Bielecka-Dabrowa Agata, S. Aronow Wilbert, Rysz Jacek and Banach Maciej, Current Place of Beta-Blockers in the Treatment of Hypertension, Current Vascular Pharmacology 2010; 8 (6) . https://dx.doi.org/10.2174/157016110793563861
DOI https://dx.doi.org/10.2174/157016110793563861 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lysophosphatidic Acid and Ischemic Stroke
Vascular Disease Prevention (Discontinued) Editorial (Thematic Issue: New Horizon in the Treatment of Hypertension - Role for Ca Channel Blockers - Why do Ca Channel Blockers be Focused on?)
Current Hypertension Reviews Molecular Pathophysiology of Renal Tubular Acidosis
Current Genomics Pharmaceuticals and Cosmeceuticals Based on Soft Nanotechnology Techniques with Antioxidative, Immunostimulative and other Therapeutic Activities
Recent Patents on Nanotechnology Drug-Drug Interactions Associated with Antiplatelet Therapy
Cardiovascular & Hematological Agents in Medicinal Chemistry Validation of a Solid Phase Extraction Procedure for Identification and Quantification of Cocaine and Metabolities in Meconium Using GC/MS
Current Pharmaceutical Analysis Wet Chemistry Approaches for Synthesis of Gold Nanospheres, Nanorods and Nanostars
Current Nanoscience Exercise Training-Associated Changes in Arterial Stiffness and Endothelium-Derived Vasoactive Factors
Current Hypertension Reviews Blood Pressure Variability and Mortality in end Stage Renal Disease
Current Hypertension Reviews Blood Biomarkers in Cardioembolic Stroke
Current Cardiology Reviews Supplementation with Oligonol, Prevents Weight Gain and Improves Lipid Profile in Overweight and Obese Saudi Females
Current Nutrition & Food Science Calcium Intake Requirements Along the Life Cycle and Associated Factors
Current Nutrition & Food Science Molecular Mechanisms Involving Sigma-1 Receptor in Cell Apoptosis of BV-2 Microglial Cells Induced by Methamphetamine
CNS & Neurological Disorders - Drug Targets “Tripping out” with the TRP Superfamily and TRPV1 for Novel Neuroprotection
Current Neurovascular Research Clinical Thiazolidinediones as PPARγ Ligands with the Potential for the Prevention of Cardiovascular Disease in Diabetes
Current Diabetes Reviews Risk Factors for Node Affectation and Recurrence in Endometrial Cancer
Current Women`s Health Reviews Clinical Application of PET Myocardial Perfusion Imaging
Current Medical Imaging Adrenomedullin in Hypertension
Current Hypertension Reviews New Orodispersible Mini Tablets of Enalapril Maleate by Direct Compression for Pediatric Patients
Current Drug Delivery Epigenetic Modulation of Myocardial Angiogenic Balance: An Emerging Therapeutic Perspective for Adult Failing Heart
Current Angiogenesis (Discontinued)